Figure 5
From: A microRNA signature of response to erlotinib is descriptive of TGFβ behaviour in NSCLC
A549 and PC9 cells exit the cell cycle regardless of treatment with TGFβ or SB-431542. The graph reflects the percentage of (a) A549 or (b) PC9 cell populations in G0-G1 phase of the cell cycle at 24, 72, and 168 hours following treatment. Significance was determined using an unpaired t-test comparing the 72 and 168 hour time points individually to the 24 hour time point of the same treatment. (c) A two-way ANOVA was utilized to determine the significance of treatment and/or time point reflective of the percentage of cells in the G0-G1 phase of the cell cycle.
